Translational Health Science and Technology Institute
Haryana
About Company
Description
Translational biotech research
Contact Information
Primary Phone
Primary Email
Website
Registered Address
State
Haryana
Country
India
Business Information
Business Types
Manufacturer
API Supplier
Manufacturing Units
1
Legal & Compliance
Certifications & Approvals
WHO-GMP
Not Certified
ISO
Not Certified
GMP
Not Certified
FSSAI
Not Certified
USFDA
Not Approved
EU-GMP
Not Certified
UK-MHRA
Not Approved
WHO Prequalified
No
PCD/Franchise Information
PCD Franchisor
No
Products
Total products: 20
| Product Name | Dosage Form | Composition | Therapeutic Category |
|---|---|---|---|
| 230k + patients Enrolled in Livaβs lifestyle change programmes | - | k + patients Enrolled in Liva | - |
| 230k + patients Enrolled in Livaβs lifestyle change programmes | - | k + patients Enrolled in Liva | - |
| Emerging roles of IL-9 and Th9 cells in respiratory viral illnesses New | - | - | Respiratory |
| Emerging roles of IL-9 and Th9 cells in respiratory viral illnesses New | - | - | Respiratory |
| Gestational diabetes | - | - | Antidiabetics |
| Gestational diabetes | - | - | Antidiabetics |
| Gestational diabetes Comprehensive healthy lifestyle support for women at risk of gestational diabetes. | - | - | Antidiabetics |
| Gestational diabetes Comprehensive healthy lifestyle support for women at risk of gestational diabetes. | - | - | Antidiabetics |
| Hypertension Personalised programmes for blood pressure management through lifestyle changes. | - | - | Antihypertensives |
| Hypertension Personalised programmes for blood pressure management through lifestyle changes. | - | - | Antihypertensives |
| Mesenchymal stem cells alleviate experimental cerebral malaria disease severity by inducing RoRΞ³t+ Foxp3+ T regulatory (Tr 17) cells and modulating the dysregulated Th17/Treg axis. | - | t+ Foxp | - |
| Mesenchymal stem cells alleviate experimental cerebral malaria disease severity by inducing RoRΞ³t+ Foxp3+ T regulatory (Tr 17) cells and modulating the dysregulated Th17/Treg axis. | - | t+ Foxp | - |
| Prediabetes | - | - | Antidiabetics |
| Prediabetes | - | - | Antidiabetics |
| Prediabetes Early intervention programmes to prevent diabetes progression. | - | - | Antidiabetics |
| Prediabetes Early intervention programmes to prevent diabetes progression. | - | - | Antidiabetics |
| Type 2 diabetes | - | - | Antidiabetics |
| Type 2 diabetes | - | - | Antidiabetics |
| Type 2 diabetes Structured interventions for prevention, management, and remission support. | - | - | Antidiabetics |
| Type 2 diabetes Structured interventions for prevention, management, and remission support. | - | - | Antidiabetics |
Company Status
Status
Active
Verification
Verified
Statistics
Profile Views
71
Total Inquiries
0